Global Enbrel Market Size Likely to Surpass at a CAGR of 3.7% By 2033

As per the current market research conducted by the CMI Team, the global Enbrel Market size is expected to record a CAGR of 3.7% from 2023 to 2032. In 2022, the market size is projected to reach a valuation of USD 15.5 billion. By 2032, the valuation is anticipated to reach USD 23.2 billion.

Enbrel Market: Growth Factors and Dynamics

• Escalating Autoimmune Disease Prevalence: The increasing occurrence of autoimmune disorders, such as rheumatoid arthritis and psoriatic arthritis, stimulates the demand for Enbrel as an efficacious treatment solution.

• Biologic Therapies on the Upswing: Biologic treatments, exemplified by Enbrel, are gaining prominence due to their targeted approach and effectiveness in managing autoimmune ailments, diverging from conventional therapies.

• Expanding Indications: Enbrel’s effectiveness in treating various autoimmune diseases beyond its initial approval broadens its patient base and market potential.

• Personalized Medicine: Tailored treatment plans based on patient profiles enhance Enbrel’s effectiveness and drive demand.

• Digital Health and Telemedicine: The integration of digital health tools and telemedicine platforms enhances patient engagement, improves access, and streamlines Enbrel therapy management.

• Market Expansion in Emerging Regions: Growing healthcare infrastructure and awareness in emerging markets contribute to market expansion.

• Research and Development: Ongoing R&D efforts focus on improving Enbrel formulations, and delivery methods, and exploring new indications, ensuring its competitiveness.

• Regulatory Environment: Changes in regulatory policies and approvals affect market dynamics and pricing.

• Patient-Centric Care: A growing emphasis on patient-centric care fosters increased Enbrel adoption, as it improves patients’ quality of life.

Enbrel Market: Partnership and Acquisitions

• In 2021, Sandoz faced a setback when its request for an Enbrel biosimilar was denied for an extended eight-year period. The U.S. court rejected the petition to review a Federal Circuit decision from the previous summer, which pertained to Sandoz’s biosimilar, Erelzi, designed as an alternative to Amgen’s Enbrel for autoimmune disease treatment. This patent dispute has prevented Erelzi’s launch since 2016, further postponing its availability in the U.S. market until 2029.

• In December 2019, Clover Biopharma initiated Phase III clinical trials for SCB-808, an Etanercept Biosimilar Candidate, in China. The company marked the dosing of the inaugural patient with a subcutaneous injection of this biosimilar, developed in a prefilled syringe format for managing rheumatic diseases, encompassing ankylosing spondylitis and rheumatoid arthritis. These trials are designed to scrutinize SCB-808’s efficacy, safety, and pharmacokinetics, comparing it to the originator drug, Enbrel®, particularly in patients grappling with ankylosing spondylitis (radiographic axial spondylarthritis).

• In 2018, Samsung Bioepis executed a strategic acquisition of Celltrion, marking a significant move into the biosimilar arena. This transaction provided Samsung Bioepis with entry to Celltrion’s biosimilar portfolio, notably featuring Remsima, a biosimilar counterpart to Remicade. Remicade is another notable biological drug widely employed in the treatment of various autoimmune disorders.

• In 2016, Cipla made a strategic move by acquiring Exir Pharma, a transaction that provided Cipla entry into the biosimilar landscape. This acquisition granted Cipla access to Exir’s biosimilar portfolio, which notably included Etanercept, a biosimilar medication akin to Enbrel.

Report Scope

Enbrel Market: COVID-19 Analysis

The COVID-19 pandemic has significantly impacted the Enbrel Market.

• Supply Chain Disruptions: The pandemic disrupted global supply chains, impacting the production and distribution of pharmaceuticals, including Enbrel. This led to temporary shortages and challenges in maintaining consistent drug availability.

• Patient Access Challenges: Lockdowns, travel restrictions, and overwhelmed healthcare systems affected patients’ ability to access Enbrel. Delayed appointments, reduced hospital visits, and concerns about immunosuppressive treatments further complicated patient care.

• Telemedicine Adoption: The pandemic accelerated the adoption of telemedicine and digital health solutions. Healthcare providers increasingly used telehealth to monitor and consult with patients, ensuring ongoing Enbrel treatment.

• Clinical Trials and Research: Many clinical trials were delayed or disrupted due to COVID-19 safety concerns. This affected the development of new Enbrel formulations or expanded indications.

• Increased Demand for Biologics: COVID-19 heightened awareness of biologics like Enbrel due to their immunomodulatory properties. Some patients with autoimmune diseases were more cautious about their health and treatment choices.

• Vaccine Interactions: Concerns arose about potential interactions between Enbrel and COVID-19 vaccines. Patients sought guidance from healthcare providers on vaccination while on Enbrel treatment.

• Regulatory Flexibility: Regulatory agencies showed flexibility in drug approvals and renewals to ensure patients’ access to Enbrel and other critical medications during the pandemic.

• Economic Impact: Economic uncertainties caused by the pandemic influenced patients’ ability to afford Enbrel, potentially impacting demand.

Overall, the Enbrel market demonstrated resilience and adaptability in response to the challenges posed by the COVID-19 pandemic. Patient care and treatment continued, with healthcare systems and providers finding innovative ways to ensure access while prioritizing safety.

List of the prominent players in the Enbrel Market:

• Amgen Inc.
• Pfizer Inc.
• Novartis AG
• Samsung Bioepis Co. Ltd.
• Merck & Co. Inc.
• Sandoz International GmbH (a subsidiary of Novartis)
• Mylan N.V. (now Viatris Inc.)
• Biogen Inc.
• AbbVie Inc.
• Johnson & Johnson
• Others

The Enbrel Market is segmented as follows:

By Product

• Brands Drugs
• Biosimilar Drugs

By Application

• Rheumatoid Arthritis
• Psoriatic Arthritis
• Ankylosing Spondylitis
• Juvenile Idiopathic Arthritis

Regional Coverage:

North America

• U.S.
• Canada
• Mexico
• Rest of North America

Europe

• Germany
• France
• U.K.
• Italy
• Spain
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• New Zealand
• Australia
• South Korea
• Rest of Asia Pacific

The Middle East & Africa

• Saudi Arabia
• UAE
• Egypt
• Kuwait
• South Africa
• Rest of the Middle East & Africa

Latin America

• Brazil
• Argentina
• Rest of Latin America